Pranlukast
chemical compound
Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.
Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.
“Pranlukast” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Pranlukast, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Pranlukast” is worth following because a concise public description often conceals a longer documentary argument. Here, Pranlukast, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jan 10, 2026. The linked authority identifier is Q7238392. None of the 0 selected statements returned an explicit reference.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Pranlukast”, its source revision and the description used here.
- Expand the search: follow Pranlukast primary sources, Pranlukast archive and Pranlukast research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Pranlukast”?
- Is the terminology current, historical or disputed?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Pranlukast” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.